Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
3.050
-0.010 (-0.33%)
At close: Mar 4, 2026, 4:00 PM EST
3.050
0.00 (0.00%)
After-hours: Mar 4, 2026, 5:38 PM EST
Neumora Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 63.29 | 62.54 | 45.48 | 31.12 | 24.55 | 8.39 | |
| Research & Development | 177.31 | 200.93 | 142.72 | 91.75 | 55.78 | 17.31 | |
| Operating Expenses | 240.6 | 263.46 | 188.19 | 122.87 | 80.32 | 25.71 | |
| Operating Income | -240.6 | -263.46 | -188.19 | -122.87 | -80.32 | -25.71 | |
| Interest & Investment Income | 11.1 | 19.93 | 16.61 | 4.56 | - | - | |
| Other Non Operating Income (Expenses) | -0.48 | -0.08 | -0.17 | 0.41 | 0.01 | -0.08 | |
| EBT Excluding Unusual Items | -231.17 | -243.61 | -171.75 | -117.9 | -80.31 | -25.79 | |
| Merger & Restructuring Charges | - | - | - | - | - | -0.7 | |
| Other Unusual Items | - | - | - | - | - | -3.28 | |
| Pretax Income | -236.17 | -243.61 | -235.66 | -130.9 | -237.31 | -99.27 | |
| Income Tax Expense | 0.13 | 0.18 | 0.27 | - | - | - | |
| Net Income | -236.3 | -243.79 | -235.93 | -130.9 | -237.31 | -99.27 | |
| Net Income to Common | -236.3 | -243.79 | -235.93 | -130.9 | -237.31 | -99.27 | |
| Shares Outstanding (Basic) | 161 | 159 | 65 | 27 | 22 | 13 | |
| Shares Outstanding (Diluted) | 161 | 159 | 65 | 27 | 22 | 13 | |
| Shares Change (YoY) | 2.49% | 145.12% | 138.99% | 24.25% | 68.46% | - | |
| EPS (Basic) | -1.46 | -1.53 | -3.63 | -4.81 | -10.84 | -7.64 | |
| EPS (Diluted) | -1.46 | -1.53 | -3.63 | -4.81 | -10.84 | -7.64 | |
| Free Cash Flow | -208.07 | -182.94 | -163.4 | -115.41 | -76.24 | -28.06 | |
| Free Cash Flow Per Share | -1.29 | -1.15 | -2.51 | -4.24 | -3.48 | -2.16 | |
| EBITDA | -240.24 | -262.83 | -187.53 | -122.28 | -79.79 | -25.6 | |
| D&A For EBITDA | 0.36 | 0.63 | 0.67 | 0.59 | 0.54 | 0.11 | |
| EBIT | -240.6 | -263.46 | -188.19 | -122.87 | -80.32 | -25.71 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.